Valuation: Galapagos NV

Market Cap 1.71B 1.96B 1.61B 1.47B 2.76B 187B 2.76B 19.32B 7.46B 95.69B 7.36B 7.2B 308B P/E 2026 *
-13.9x
P/E 2027 * -5.66x
Enterprise Value -718M -821M -674M -615M -1.16B -78.49B -1.16B -8.09B -3.12B -40.09B -3.08B -3.02B -129B EV / Sales 2026 *
-6.12x
EV / Sales 2027 * 2.37x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.96B
-0.21%+3.86%+3.75%+29.41% 47.86B
+0.73%+0.83%+45.37%+33.92% 44.46B
-1.10%+4.64%+10.68%+91.31% 41.85B
-0.05%-2.36%+332.76%+548.47% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
+0.14%+2.53%+27.39%+158.30% 17.59B
-3.40%-7.02% - - 15.6B
-3.17%+2.36%+22.45%+39.68% 15.69B
-0.47%+9.70%-8.77% - 13.93B
Average -0.79%+2.66%+55.47%+135.30% 29.82B
Weighted average by Cap. -0.54%+1.88%+68.90%+143.20%

Financials

2026 *2027 *
Net sales 117M 134M 110M 101M 189M 12.82B 189M 1.32B 510M 6.55B 504M 493M 21.11B 84.62M 96.83M 79.53M 72.58M 136M 9.26B 136M 954M 368M 4.73B 364M 356M 15.24B
Net income -40.7M -46.57M -38.25M -34.9M -65.51M -4.45B -65.52M -459M -177M -2.27B -175M -171M -7.33B -213M -243M -200M -182M -342M -23.27B -342M -2.4B -926M -11.88B -914M -894M -38.31B
Net Debt -2.43B -2.78B -2.28B -2.08B -3.91B -266B -3.91B -27.42B -10.58B -136B -10.44B -10.22B -438B -1.51B -1.73B -1.42B -1.3B -2.43B -165B -2.43B -17.06B -6.58B -84.48B -6.5B -6.36B -272B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!